There is insufficient evidence for population screening. Screening for anti-transglutaminase antibodies may detect asymptomatic coeliac disease but may also cause harm associated with further investigations and overtreatment. In 2017, the US Preventive Services Task Force (USPSTF) found inadequate evidence on the accuracy of screening for coeliac disease; the potential benefits and harms of screening versus not screening or targeted versus universal screening; and the potential benefits and harms of treatment of screen-detected coeliac disease.³

There are no additional recommendations for this specific population.

Testing for coeliac disease is appropriate for:^4,5

• people with signs and symptoms, such as:
  • persistent unexplained gastrointestinal symptoms
  • delayed growth or weight loss
  • prolonged fatigue
  • persistent mouth ulcers
  • iron, vitamin B12 or folate deficiency
• first-degree relative of a patient with coeliac disease
• people with associated conditions, such as:
  • type 1 diabetes
  • autoimmune thyroid disease
  • irritable bowel syndrome in adults.

For further information on coeliac disease and patient information:
Coeliac Australia website